These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 11905679)

  • 1. PSA doubling times.
    Newcombe H
    Lancet Oncol; 2000 Sep; 1(1):14-5. PubMed ID: 11905679
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of high-risk prostate cancer: role of prostate-specific antigen, PSA doubling time, and PSA velocity.
    Heidenreich A
    Eur Urol; 2008 Nov; 54(5):976-7; discussion 978-9. PubMed ID: 18640768
    [No Abstract]   [Full Text] [Related]  

  • 3. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostate specific antigen (PSA): impact of a seric marker on the diagnosis and therapeutic management of cancers of the prostate].
    Chauvet B; Jacob T; Davin JL; Berger C; Vincent P; Reboul F
    Bull Cancer Radiother; 1996; 83(4):334-44. PubMed ID: 9081335
    [No Abstract]   [Full Text] [Related]  

  • 5. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
    BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with prednisolone of hormone-refractory prostate cancer.
    Fuse H; Nozaki T; Fujiuchi Y; Mizuno I; Nagakawa O; Okumura A
    Arch Androl; 2006; 52(1):35-8. PubMed ID: 16338867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of neoadjuvant prostate-specific antigen kinetics on biochemical failure and prostate cancer mortality: results from a prospective patient database.
    Foo M; Lavieri M; Pickles T
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):385-92. PubMed ID: 22652112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative importance of PSA in prostate cancer treatment.
    Unger HA; Kane RD; Fox KM; Gandhi S; Alzola C; Lamerato L; Newling D; Kumar S
    Urol Oncol; 2005; 23(4):238-45. PubMed ID: 16018938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy.
    Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Huang CY; Pu YS; Yu CC; Huang CH
    Prostate; 2011 Aug; 71(11):1189-97. PubMed ID: 21656829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
    J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostate specific antigen: utilization modalities and interpretation].
    Hannoun-Levi JM; Ginot A; Thariat J
    Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locally advanced prostate cancer: three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy.
    Valentini AL; Gui B; D'Agostino GR; Mattiucci G; Clementi V; Di Molfetta IV; Bonomo P; Mantini G
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):719-24. PubMed ID: 22436789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hormonal therapy in prostate brachytherapy. Counterpoint.
    Merrick GS
    Brachytherapy; 2003; 2(1):2-4. PubMed ID: 15062157
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of hormonal therapy in prostate brachytherapy. Point.
    Stock RG
    Brachytherapy; 2003; 2(1):1-2. PubMed ID: 15062156
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is an improved PSA screening test in sight?
    Savage L
    J Natl Cancer Inst; 2007 Oct; 99(20):1503-4. PubMed ID: 17925529
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of commercially available soy products on PSA in androgen-deprivation-naïve and castration-resistant prostate cancer.
    Joshi M; Agostino NM; Gingrich R; Drabick JJ
    South Med J; 2011 Nov; 104(11):736-40. PubMed ID: 22024780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
    Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
    Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary hormonal manipulations in the treatment of castration refractory prostate cancer.
    Agarwal N; Vogelzang NJ
    BJU Int; 2011 Jul; 108(2):227-8. PubMed ID: 21410863
    [No Abstract]   [Full Text] [Related]  

  • 20. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.